Search Results - oncology

8 Results

Sort By:

Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene

Abstract: The Zbtb7b gene encodes the zinc finger transcription factor ThPOK (also known as cKrox) that promotes CD4 lineage differentiation in immature T cells. CD4+ T cells, also known as “helper” T cells, are critical for long-term immunity against pathogens as well as for promoting CD8+ “effector” T cell and effective B cell responses. ThPOK is...

Published: 5/8/2024 | Inventor(s):

Keywords(s): Autoimmunity, Bosselut, CANCER, CD4, cKrox, Helper T Cell, Infection, LYMPHOCYTE, Memory T Cell, Oncology, ThPOK, transgenic mice, Zbtb7b, Zinc Finger Transcription Factor

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Research Materials, TherapeuticArea > Immunology

Human and Improved Murine Monoclonal Antibodies Against CD22

Abstract: CD22 is a common cell surface glycoprotein expressed in B-cells and present in B-cell lymphomas; e.g., hairy cell leukemia (HCL), non-Hodgkins lymphoma (NHL), chronic lymphoblastic leukemia (CLL), and other cancers. It is therefore a target for cancer immunotherapy. Conjugation of anti-CD22 monoclonal antibodies with toxins or drugs has shown...

Published: 8/14/2024 | Inventor(s): Dimiter Dimitrov, Xiaodong Xiao, Ira Pastan

Keywords(s): antibodies, ANTIGEN, B-CELL, B-Cell Lymphoma, Bcl, CANCER, CD22, Chronic Lymphoblastic Leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Human, monoclonal, NHL, non-Hodgkins lymphoma, Oncology

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)

Abstract: Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC) independent manner to...

Published: 4/8/2024 | Inventor(s): Terry Fry, Crystal Mackall, Rimas Orentas, Haiying Qin, Waleed Haso

Keywords(s): Acute Lymphoblastic Leukemia, ALL, BISPECIFIC, Bivalent, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Antisense Oligonucleotides against Cancer Cell Migration and Invasion

Abstract: Advanced stage cancers are typically marked by metastases of the primary cancer to secondary sites such as lungs, liver, and bones. Such metastatic cancers result in strikingly low 5-year survival rates, underscoring the need for novel therapeutics. For example, bone metastasis of primary breast cancer has a 5-year survival rate of 13%, lung...

Published: 4/8/2024 | Inventor(s): Stavroula Mili

Keywords(s): Antisense, APC, CANCER, Invasion, Metastasis, MIGRATION, Mili, Net1, OLIGO, oligonucleotide, Oncology, Rab13, RNA

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics

New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer

Abstract: Polo-like kinase 1 (Plk1), a member of the Polo-like kinase family, plays a critical role in regulating mitosis and cell cycle progression. Aberrant expression of Plk1 has been observed in a variety of human cancers, and it is known to be associated with tumorigenesis as well as poor prognosis in cancer patients. Unlike normal cells, some...

Published: 4/8/2024 | Inventor(s): Kyung Lee, Kenneth Jacobson, Celeste Alverez, Jung-Eun Park

Keywords(s): CANCER, cell cycle, Heterocyclic Scaffold, Lee, mitosis, Oncology, PBD, plk1, Polo-Box Domain, Polo-Like Kinase 1, PRODRUGS, Triazoloquinazolinone

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology

Personalized Tumor Vaccine and Use Thereof for Cancer Immunotherapy

Abstract: Immune checkpoint inhibitors (ICIs) vastly improved the outcome of various advanced cancers; however, many are less likely to respond to single-agent ICI. Tumors with low T-cell infiltration are "immunologically cold" and less likely to respond to single-agent ICI therapy. This diminished response is presumably due to the lack of neoantigens...

Published: 4/8/2024 | Inventor(s): Zhengping (Ping) Zhuang, Karel Pacak, Jan Zenka, Rogelio Medina, Herui Wang, Sze Chun (Winson) Ho

Keywords(s): Anti-CD40-Monoclonal Antibody, CANCER, ICI, Immune Checkpoint Inhibitors, Mannan-BAM, Oncology, TLR, Toll-like receptor, Tumor Vaccine, Zhuang

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)

Abstract: Treatment of B-cell acute lymphoblastic leukemia (ALL) and lymphoma using chimeric antigen receptors (CARs) targeting B-cell surface protein CD19 has demonstrated impressive clinical results in children and young adults. Despite the promising results from CD19 CAR therapy, up to 40% of patients, who initially achieve remission, eventually...

Published: 8/14/2024 | Inventor(s): Haiying Qin, Terry Fry, Crystal Mackall

Keywords(s): Acute Lymphoblastic Leukemia, ALL, BICISTRONIC, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration

SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation

Abstract: The Transforming Growth Factor Beta (TGF-ß) ligands (i.e., TGF-ß1, -ß2, -ß3) are key regulatory proteins in animal physiology. Disruption of normal TGF-ß signaling is associated with many diseases from cancer to fibrosis. In mice and humans, TGF-ß activates TGF-ß receptors (e.g., TGFBR1), which activates SMAD proteins that alter gene expression...

Published: 5/23/2024 | Inventor(s): Lalage Wakefield, Yu-an Yang, Sushil Rane, Caroline Hill

Keywords(s): Animal Model, CANCER, EGFP, Fibrosis, Wakefield, mothers against decapentaplegic homolog 3, Oncology, Reporter Mouse, SMAD3, TGF-ß, Transforming Growth Factor Beta

Category(s): TherapeuticArea > Endocrinology, TherapeuticArea > Oncology, Application > Research Materials, Collaboration Sought > Licensing, TherapeuticArea > Cardiology, TherapeuticArea > Immunology, TherapeuticArea > Neurology